Literature DB >> 2900601

The functional importance of beta 1 and beta 2 adrenoceptors in the human heart.

O E Brodde1.   

Abstract

Radioligand binding studies have demonstrated convincingly the coexistence of beta 1 and beta 2 adrenoceptors in the human heart. Both subtypes are involved in the increase in tissue levels of cyclic adenosine monophosphate in isolated, electrically driven, human right atria and in the activation of adenylate cyclase in human cardiac membrane preparations. In isolated, electrically driven strips of human right atria, isoproterenol increased contractile force through stimulation of both beta 1 and beta 2 adrenoceptors, while the selective beta 2-adrenoceptor agonist, procaterol, caused its positive inotropic effect predominantly through beta 2-adrenoceptor stimulation. Norepinephrine, however, increased contractile force solely via beta 1-adrenoceptor stimulation. In this preparation, dobutamine also acted as a full agonist, producing a positive inotropic effect through stimulation of both beta-adrenoceptor subtypes. Dopexamine hydrochloride, on the other hand, having an approximately 10-fold greater affinity for right atrial beta 2 than for beta 1 adrenoceptors, acted as a partial agonist (maximal positive inotropic effect: about 30% that of isoproterenol). Similar effects have been obtained in human right and left ventricular strips; thus, there can be no doubt that cardiac beta 2 adrenoceptors can contribute to the positive inotropic effects of beta-adrenoceptor agonists in the human heart. Besides mediating positive inotropic effects, right atrial beta 2 adrenoceptors may be involved in the regulation of heart rate since, in healthy volunteers, the selective beta 2-adrenoceptor antagonist, ICI 118,551, was more potent than the selective beta 1-adrenoceptor antagonist, bisoprolol, in antagonizing isoproterenol-induced tachycardia, when both antagonists were administered in doses that selectively occupied more than 90% of beta 2 and beta 1 adrenoceptors, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900601     DOI: 10.1016/s0002-9149(88)80063-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Do human cardiac beta-2 adrenoceptors play a (patho)physiological role in regulation of heart rate and/or contractility?

Authors:  O E Brodde; H R Zerkowski
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 2.  Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

Authors:  T Meinertz; H Drexler; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 3.  Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.

Authors:  R J Milne; M M Buckley
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

4.  Beta-receptor responsiveness after desipramine treatment.

Authors:  R Pohl; G N Pandey; V K Yeragani; R Balon; J M Davis; R Berchou
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Differential presynaptic modulation of noradrenaline release in human atrial tissue in normoxia and anoxia.

Authors:  G Münch; T Kurz; T Urlbauer; M Seyfarth; G Richardt
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses.

Authors:  Christopher Kable Means; Shigeki Miyamoto; Jerold Chun; Joan Heller Brown
Journal:  J Biol Chem       Date:  2008-02-24       Impact factor: 5.157

7.  Lipolytic catecholamine resistance due to decreased beta 2-adrenoceptor expression in fat cells.

Authors:  F Lönnqvist; H Wahrenberg; L Hellström; S Reynisdottir; P Arner
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

8.  Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man.

Authors:  C de Mey; K Beithaupt; D Palm; U Fuhr; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease.

Authors:  M J Kendall; I Rajman
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

10.  Arrhythmogenic potential of dopexamine hydrochloride during halothane anaesthesia in dogs.

Authors:  S M Neustein; I Dimich; I Sampson; A Sadeghi; C Mezrow; H Shiang
Journal:  Can J Anaesth       Date:  1994-06       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.